The European Medicines Agency’s advisory group CHMP has adopted a positive opinion recommending approval of Mylan N.V.’s (NASDAQ:MYL) clopidogrel/acetylsalicylic acid, a generic version of Sanofi’s (NASDAQ:SNY) heart med DuoPlavin.
A final decision from the European Commission usually takes ~60 days.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.